Limits...
The comparison of surgical patients with primary hepatic squamous cell carcinoma or adenosquamous carcinoma and surgical patients with hepatocellular carcinoma.

Yan L, Xie F, Yang C, Yu L, Zheng T, Fu J, Yang J - World J Surg Oncol (2015)

Bottom Line: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9).Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294).And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

View Article: PubMed Central - PubMed

Affiliation: Department of Special Treatment and Liver Transplantation, Eastern Hepatobiliary Hospital, the Second Military Medical University, 255 Changhai Road, Shanghai, 200438, China. hunanxiefeng@yahoo.com.cn.

ABSTRACT

Background: There are still several controversies and ambiguities in the aspects of primary hepatic squamous cell carcinoma and primary hepatic adenosquamous carcinoma. To further clarify the specific features of these two infrequent diseases and provide beneficial propose for clinical decision, we did this retrospective study.

Methods: We reviewed the clinical features and outcomes of three primary hepatic squamous cell carcinoma (SCC) patients and six primary hepatic adenosquamous carcinoma (ASC) patients from January 1998 to December 2011 in Eastern Hepatobiliary Surgery Hospital in China. Meanwhile, 40 hepatocellular carcinoma (HCC) patients and 26 metastatic hepatic SCC or ASC patients who were hospitalized in the same period were also reviewed to make a comparison. In order to find out the definite survival information of SCC and ASC patients, 30 previous studies containing 37 primary hepatic SCC (16) and ASC (21) patients were reviewed, and their information of survival was analyzed together with the included patients in our hospital.

Results: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9). On the pathologic performance, primary SCC/ASC tumor was rarely accompanied with tumor capsule. They presented peripheral hepatic lymph node metastasis more likely and showed low proportion of microvascular invasion. The median survival time of primary hepatic SCC/ASC patients after liver resection (LR) was 15 months. And the 1-, 3-, 5-year survival rates after LR were 60%, 24%, and 12%, respectively. Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294). The median survival time after LR for primary SCC and ASC patients was respectively 23 months and 13 months.

Conclusions: The comprehensive application of some clinical characteristics, histopathologic features, and imaging findings may be useful for us in making definite diagnoses for primary hepatic SCC and ASC patients preoperatively. And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier cumulative survival curves of the total primary SCC/ASC group(added 37 patients from previous studies)and HCC group of patients for overall survival(OS)after liver resection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4358902&req=5

Fig3: Kaplan-Meier cumulative survival curves of the total primary SCC/ASC group(added 37 patients from previous studies)and HCC group of patients for overall survival(OS)after liver resection.

Mentions: From the review of 30 previous studies, we extracted the survival information of 37 primary SCC (16, 43.2%) and ASC (21, 56.8%) patients, and their survival data was mixed together with our patients’ data to conduct the survival analysis. All of the 37 primary SCC/ASC patients from previous studies and our 9 primary SCC/ASC patients were defined as total primary SCC/ASC group (46 patients), which would be compared with those 40 HCC patients. The median survival time after LR of the total primary SCC/ASC patients was 15 months, which was the same with our included 9 SCC/ASC patients in our hospital. And the mean survival time after LR was 26.187 ± 4.876 months. The 1-, 3-, 5-year survival rates after LR for these primary SCC/ASC patients were 60%, 24%, 12%, respectively. We also did not find any significant difference when compared with HCC patients (log rank χ2 = 1.100, P = 0.294, Figure 3). At the same time, we compared all of primary SCC patients (19 patients) and primary ASC patients (27 patients) with HCC patients (40 patients), respectively. The median survival time after LR for primary SCC and ASC patients was 23 and 13 months. The 1-, 3-, 5-year survival rates after LR were 72%, 27%, and 18% and 51%, 21%, and 7% for SCC patients and ASC patients. Though the survival rates appeared to be different, from the analysis of comparison result, no significant difference was found when we compared the SCC and ASC patients with HCC patients respectively (log rank χ2 = 4.330, P = 0.115, Figure 4). This result was similar with what we obtained from the comparison of patients in our hospital. So from the statistical analysis results, we found that the survival after LR for primary hepatic SCC and ASC patients seemed similar with HCC patients.Figure 3


The comparison of surgical patients with primary hepatic squamous cell carcinoma or adenosquamous carcinoma and surgical patients with hepatocellular carcinoma.

Yan L, Xie F, Yang C, Yu L, Zheng T, Fu J, Yang J - World J Surg Oncol (2015)

Kaplan-Meier cumulative survival curves of the total primary SCC/ASC group(added 37 patients from previous studies)and HCC group of patients for overall survival(OS)after liver resection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4358902&req=5

Fig3: Kaplan-Meier cumulative survival curves of the total primary SCC/ASC group(added 37 patients from previous studies)and HCC group of patients for overall survival(OS)after liver resection.
Mentions: From the review of 30 previous studies, we extracted the survival information of 37 primary SCC (16, 43.2%) and ASC (21, 56.8%) patients, and their survival data was mixed together with our patients’ data to conduct the survival analysis. All of the 37 primary SCC/ASC patients from previous studies and our 9 primary SCC/ASC patients were defined as total primary SCC/ASC group (46 patients), which would be compared with those 40 HCC patients. The median survival time after LR of the total primary SCC/ASC patients was 15 months, which was the same with our included 9 SCC/ASC patients in our hospital. And the mean survival time after LR was 26.187 ± 4.876 months. The 1-, 3-, 5-year survival rates after LR for these primary SCC/ASC patients were 60%, 24%, 12%, respectively. We also did not find any significant difference when compared with HCC patients (log rank χ2 = 1.100, P = 0.294, Figure 3). At the same time, we compared all of primary SCC patients (19 patients) and primary ASC patients (27 patients) with HCC patients (40 patients), respectively. The median survival time after LR for primary SCC and ASC patients was 23 and 13 months. The 1-, 3-, 5-year survival rates after LR were 72%, 27%, and 18% and 51%, 21%, and 7% for SCC patients and ASC patients. Though the survival rates appeared to be different, from the analysis of comparison result, no significant difference was found when we compared the SCC and ASC patients with HCC patients respectively (log rank χ2 = 4.330, P = 0.115, Figure 4). This result was similar with what we obtained from the comparison of patients in our hospital. So from the statistical analysis results, we found that the survival after LR for primary hepatic SCC and ASC patients seemed similar with HCC patients.Figure 3

Bottom Line: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9).Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294).And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

View Article: PubMed Central - PubMed

Affiliation: Department of Special Treatment and Liver Transplantation, Eastern Hepatobiliary Hospital, the Second Military Medical University, 255 Changhai Road, Shanghai, 200438, China. hunanxiefeng@yahoo.com.cn.

ABSTRACT

Background: There are still several controversies and ambiguities in the aspects of primary hepatic squamous cell carcinoma and primary hepatic adenosquamous carcinoma. To further clarify the specific features of these two infrequent diseases and provide beneficial propose for clinical decision, we did this retrospective study.

Methods: We reviewed the clinical features and outcomes of three primary hepatic squamous cell carcinoma (SCC) patients and six primary hepatic adenosquamous carcinoma (ASC) patients from January 1998 to December 2011 in Eastern Hepatobiliary Surgery Hospital in China. Meanwhile, 40 hepatocellular carcinoma (HCC) patients and 26 metastatic hepatic SCC or ASC patients who were hospitalized in the same period were also reviewed to make a comparison. In order to find out the definite survival information of SCC and ASC patients, 30 previous studies containing 37 primary hepatic SCC (16) and ASC (21) patients were reviewed, and their information of survival was analyzed together with the included patients in our hospital.

Results: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9). On the pathologic performance, primary SCC/ASC tumor was rarely accompanied with tumor capsule. They presented peripheral hepatic lymph node metastasis more likely and showed low proportion of microvascular invasion. The median survival time of primary hepatic SCC/ASC patients after liver resection (LR) was 15 months. And the 1-, 3-, 5-year survival rates after LR were 60%, 24%, and 12%, respectively. Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294). The median survival time after LR for primary SCC and ASC patients was respectively 23 months and 13 months.

Conclusions: The comprehensive application of some clinical characteristics, histopathologic features, and imaging findings may be useful for us in making definite diagnoses for primary hepatic SCC and ASC patients preoperatively. And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

No MeSH data available.


Related in: MedlinePlus